Alumis (ALMS) Net Income towards Common Stockholders Growth (1y) (2024 - 2026)

Alumis (ALMS) Net Income towards Common Stockholders Growth (1y) (2024 - 2026) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Income Growth (1y) (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	6.48%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-6.81%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	92.37%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	151.28%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-99.90%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-12.04%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	327.74%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	95.87%
10	Alumis	3.25 Bn	2.75 Bn	-	-339.52%

Download Data